

Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia

David C. Dale, Richard E. Person, Audrey Anna Bolyard, Andrew G. Aprikyan, Cindy Bos, Mary Ann Bonilla, Laurence A. Boxer, George Kannourakis, Cornelia Zeidler, Karl Welte, Kathleen F. Benson, and Marshall Horwitz

Congenital neutropenia and cyclic neutropenia are disorders of neutrophil production predisposing patients to recurrent bacterial infections. Recently the locus for autosomal dominant cyclic neutropenia was mapped to chromosome 19p13.3, and this disease is now attributable to mutations of the gene encoding neutrophil elastase (the *ELA2* gene). The authors hypothesized that congenital neutropenia is also due to mutations of neutrophil elastase. Patients with congenital neutropenia, cyclic neutropenia, or Shwachman-Diamond syndrome were referred to the Severe Chronic Neutropenia International Registry. Referring physicians provided he-

matologic and clinical data. Mutational analysis was performed by sequencing polymerase chain reaction (PCR)-amplified genomic DNA for each of the 5 exons of the neutrophil *ELA2* gene and 20 bases of the flanking regions. RNA from bone marrow mononuclear cells was used to determine if the affected patients expressed both the normal and the abnormal transcript. Twenty-two of 25 patients with congenital neutropenia had 18 different heterozygous mutations. Four of 4 patients with cyclic neutropenia and 0 of 3 patients with Shwachman-Diamond syndrome had mutations. For 5 patients with congenital neutropenia having mutations predicted to alter RNA splicing or transcript

structure, reverse transcriptase-PCR showed expression of both normal and abnormal transcripts. In cyclic neutropenia, the mutations appeared to cluster near the active site of the molecule, whereas the opposite face was predominantly affected by the mutations found in congenital neutropenia. This study indicates that mutations of the gene encoding neutrophil elastase are probably the most common cause for severe congenital neutropenia as well as the cause for sporadic and autosomal dominant cyclic neutropenia. (Blood. 2000;96:2317-2322)

© 2000 by The American Society of Hematology

Introduction

Cyclic and congenital neutropenia are severe disorders of neutrophil production that cause lifelong problems with recurrent infections. Cyclic neutropenia was first recognized as a distinct entity in 1910 because of the extremely regular recurrence of neutropenia, fever, and mouth ulcers in a 19-month-old boy.¹ Its autosomal dominant pattern of inheritance was first suggested by de Berardinis and Reiman in 1949² and confirmed by Morley and colleagues³ in a study of 5 families in 1967. Characteristically in cyclic neutropenia, the blood neutrophil counts oscillate with a 21-day periodicity with extremely low circulating neutrophils at the nadir of the cycle and peak counts that are less than 2000/ μ L. The diagnosis of cyclic neutropenia depends on serial measurements of absolute neutrophil counts over a period of several weeks.⁴

Congenital neutropenia is a less well-defined entity and is generally regarded as a heterogeneous disorder. In 1954, Kostmann described autosomal recessive congenital neutropenia in a large Swedish family.⁵ Subsequently many other cases of severe congenital neutropenia have been described,⁶ usually sporadic cases as well

as cases with autosomal dominant inheritance.⁷ Currently, the diagnosis of severe congenital neutropenia is made if the onset is recognized at birth or soon thereafter, blood neutrophil counts are less than 200/ μ L, the hematocrit or hemoglobin and platelet levels are normal or near normal, and the marrow shows a selective defect in neutrophil formation with many promyelocytes but relatively few myelocytes, metamyelocytes, and neutrophils or "promyelocytic maturation arrest."

We recently reported positional cloning studies that map the locus for autosomal dominant cyclic neutropenia to chromosome 19p13.3, the locus for several serine proteases.⁸ Mutational analysis in 13 families and a sporadic case of cyclic neutropenia showed 7 different mutations of the gene for neutrophil elastase (*ELA2*), a serine protease synthesized chiefly at the promyelocytic stage in neutrophil development. The same mutations were found in several families and clustered around the active site of this enzyme. Because patients with congenital neutropenia have many hematologic features that are similar to patients with cyclic neutropenia, we hypothesized that they might result from mutations in the same

From the Divisions of Hematology and Medical Genetics, Department of Medicine and the Markey Molecular Medicine Center, University of Washington School of Medicine, Seattle, WA; St Barnabas Medical Center, West Orange, NJ; University of Michigan, Ann Arbor, MI; University of Ballarat, Ballarat, Australia; and Medizinische Hochschule, Hannover, Germany.

Submitted April 4, 2000; accepted June 7, 2000.

Supported by grants from Amgen, Inc, Thousand Oaks, CA; the National Institutes of Health (NIH) DK RO1 18951 and AI20065; the Markey Trust and the Doris Duke Charitable Foundation (T98006); the Leukemia Society of America; the American Cancer Society; the Leukemia Research Foundation; the National Leukemia Research Association; and UW Center grant number P30 ES07033 from the National Institute of Environmental Health Sciences, NIH.

Paid for in part by Amgen, Thousand Oaks, CA. D.C.D., M.A.B., L.A.B., G.K., and K.W. are consultants to Amgen, and D.C.D. and K.W. receive research support from Amgen. Amgen paid part or all of the salaries of R.E.P., A.A.B., A.G.A., and C.Z. while they were engaged in this study.

Reprints: David C. Dale, Severe Chronic Neutropenia International Registry, Department of Medicine, University of Washington School of Medicine, Box 356422, Seattle, WA, 98195-6422; e-mail: dcdale@u.washington.edu.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.

© 2000 by The American Society of Hematology

Table 1. Characteristics of patients with congenital neutropenia

Subject	Age (y)	Gender	ANC ¹ /mm ³	AMC ² /mm ³	Platelets ³ × 10 ³ /mm ³	HCT ⁴ %	Bone marrow evaluations ⁵					Elastase mutations		
							Mblast %	Promyelo %	Myelo %	Meta %	B/Poly %	Exon/intron	Nucleotide ⁶	Effect on protein ⁷
1	4	M	0	2943	558	36	Severe maturation arrest					Exon 2	G34010A	A28T
2	13	M	0	1891	348	32	2	5	23	7	2	Exon 2	T34020C	I31T
3	15	F	106	1484	349	36	0	6	0	0	1	Exon 2	T34052A	C42S
4	3	F	97	2928	547	30	Arrest at myelocyte, very few mature neutrophils					Exon 3	G34371A	V72M
5	8	F	126	1071	513	27	0	5	7	0	0	Exon 3	G34371A	V72M
6	11	M	0	5372	576	29	0	7	1	0	1	Exon 4	C15823T	S97L
7	3	F	79	2196	546	30	0	2	7	2	0	Exon 4	C15862T	P110L
8	15	F	159	599	403	37	0	21	19	0	0	Exon 4	C15862T	P110L
9	25	M	215	320	214	39	3	8	21	11	4	Exon 4	C15862T	P110L
10	33	F	220	740	227	32	0	4	6	2	4	Exon 4	C15862T	P110L
11	14	M	96	1088	320	25	3	11	2	0	0	Exon 4	ins5T16063	+2fs
12	18	F	33	990	483	36	0	10	1	2	0	Exon 4	del15995-16018	delV145-C152
13	4	F	0	3943	639	43	Not done					Exon 5	G16268T	G181V
14	10	F	0	1610	650	34	0	9	0	0	0	Exon 5	G16279A	G185R
15	0.4	M	34	3041	272	39	3	1	1	0	1	Exon 5	G16300T	G192Stop
16	4	M	318	504	534	35	1	10	26	15	6	Exon 5	C16313A	S196Stop
17	3	F	200	4300	722	26	Not done					Exon 5	C16323A	Y199Stop
18	5	M	0	1797	345	34	Not done					Exon 5	delC16324	Minus 1fs
19	26	F	58	1218	427	37	3	6	1	0	2	Exon 5	delC16340	Minus 1fs
20	21	M	272	318	418	37	1	4	16	1	1	Intron 3	C15805A	(ivs3 -8sa) insPQ94
21	1	F	0	1243	501	29	3	2	15	9	12	Intron 4	G16073A	(ivs4 +1sd)del V161-F170
22	33	M	124	990	235	45	6	6	4	0	0	Intron 4	G16077A	(ivs4 +5sd)del V161-F170
23	20	M	0	1449	413	34	3	9	13	3	0	no mutation		
24	50	M	199	39	150	44	0	2	2	0	1	no mutation		
25	14	M	330	465	281	37	Not done					no mutation		
Mean	14		112	1489	415	35	1	7	9	3	2			
SE	2		21	227	31	1	0	1	2	1	1			
^a Normal data														
Mean			3563	571	242	43	1	3	11	11	25			
SE			171	49	9	1	0	0	1	0	1			

^aHealthy volunteers = 39 subjects—21 males and 18 females.

¹ANC = Absolute neutrophil count. Measurement is the median of baseline counts.

²AMC = Absolute monocyte count. Measurement is the median of baseline counts.

³Measurement is the median of baseline counts.

⁴Measurement is the median of baseline counts.

⁵Mblast indicates myeloblast; Promyelo, promyelocyte; Myelo, Myelocyte; Meta, metamyelocyte; B/Polys, bands + polymorphonuclear cells.

⁶Position of nucleotides for subjects 1-5 (mutations in exon 1-3) corresponds to GenBank AC004799 and for subjects 6-21 (mutations in intron 3-exon 5) to GenBank AC010648.

⁷Numbering of splice site mutations is relative to the intron (negative)/exon (positive) boundary. Amino acid numbering begins from the first amino acid after the presignal peptide cleavage.

ins indicates insertion; del, deletion; ivs, intervening sequence; sa, splice acceptor; sd, splice donor; fs = frame shift.

gene. We found that most patients with congenital neutropenia also have neutrophil elastase mutations, results suggesting that mutations of the gene encoding neutrophil elastase cause both cyclic and severe congenital neutropenia.

Patients, materials, and methods

Patients

Patients were referred to the Severe Chronic Neutropenia International Registry (SCNIR). They or their parents or guardians gave consent for these studies under the auspices of the Human Subjects Committee of the University of Washington. Diagnoses were assigned at enrollment by established criteria of the SCNIR. The diagnosis of severe congenital neutropenia was based on at least 3 blood neutrophil counts less than 500/ μ L obtained at least 3 months after birth; a typical pattern of recurrent fevers, chronic gingivitis, and infections at irregular intervals; a bone

marrow aspirate showing "maturation arrest" at the promyelocyte or myelocyte stage; and a normal cytogenetic analysis. The diagnosis of cyclic neutropenia required serial neutrophil counts for 3 to 6 weeks showing obvious oscillations at approximately 21-day intervals. The diagnosis of Shwachman-Diamond syndrome was made based on findings of steatorrhea, short stature, and pancytopenia in children with severe neutropenia. Patients with myelodysplasia, autoimmune disorders, or previous cytotoxic chemotherapy were excluded. Healthy individuals with normal blood counts served as controls.

Blood counts and DNA analyses

Routine blood cell counts were performed in laboratories of the patients' referring physicians. DNA was extracted from peripheral blood or bone marrow cells by standard techniques. Mutational analysis was performed by directly sequencing polymerase chain reaction (PCR)-amplified genomic DNA with an ABI/PE Biosystems PRISM Big Dye terminator chemistry on an ABI/PE Biosystems 310 Analyzer (Applied Biosystems, Foster City,




Figure 1. Serial neutrophil counts for 3 patients with a diagnosis of congenital neutropenia, on no treatments, showing periods with regular oscillations of neutrophil counts. Panels C and D are for the same patient observed for 2 prolonged periods 2 years apart.

CA). Each exon of neutrophil elastase and 20 bases of the flanking regions were sequenced from both directions in each individual.

Reverse transcriptase-PCR (RT-PCR)

Total RNA was isolated from fresh Ficoll-Hypaque-separated bone marrow mononuclear cells using a RNeasy kit (Qiagen, Valencia, CA). RT-PCR used Qiagen Omniscript RT with subsequent PCR and direct DNA sequencing. The primers amplified a 728-bp complementary DNA (cDNA) fragment between exons 2 and 5, which was subsequently digested with the restriction enzyme Taq I (New England Biolabs, Bethesda, MD) to produce a 411-bp fragment of interest in normal controls.

Statistical analysis

Differences between means were compared with the Student *t* test using Prism Graph Pad Software (San Diego, CA).

Protein structure modeling

Coordinates of neutrophil elastase were obtained from the Protein Data Bank⁹ and mutations were made using the program of Jones and colleagues.¹⁰

Homology modeling was carried out with tools available in the suite of programs in the “Molecular Operating Environment” available from the Chemical Computing Group, Montreal, Quebec, (<http://www.chemcomp.com>) with the assistance of E. Adman at the University of Washington.

Results

Clinical characteristics

Hematologic data for 25 unrelated patients with congenital neutropenia are summarized in Table 1. The blood neutrophil counts were severely reduced (mean, $112 \pm 21/\mu\text{L}$) and monocyte counts increased (mean, $1489 \pm 227/\mu\text{L}$). Platelet counts were increased and hematocrit values mildly decreased in most patients. Marrow examinations showed scarce or absent neutrophils, bands, and metamyelocytes, with a typical pattern of “maturation arrest” of the neutrophil series; exceptions may be attributable to infection at the time of marrow sampling, which may transiently increase neutrophil production in these patients. In 3 patients with a diagnosis of congenital neutropenia who had long series of frequent blood counts (Table 1, patients 9, 20, and 22), there were periods with regular oscillations in blood neutrophil levels and other periods when oscillations were not apparent (Figure 1).

Two groups of neutropenic patients were studied for comparison with the patients with congenital neutropenia (Table 2). The 4 patients with cyclic neutropenia were sporadic cases with typical 21-day cycles of fever, mouth ulcers, and severe neutropenia. The 3 children with Shwachman-Diamond syndrome had neutropenia that was less severe than for the patients with congenital neutropenia.

Mutations of the neutrophil *ELA2* gene

Twenty-two of 25 patients diagnosed as having congenital neutropenia were found to have neutrophil elastase mutations. Eighteen different heterozygous mutations were detected (Table 1). Four unrelated patients had the identical mutations in exon 4 (patients 7-10). Two other unrelated patients had the same mutation in exon 3 (patients 4 and 5). Five mutations occurred in families with 2 or more affected members—3 fathers and 3 daughters, (patients 5, 7,

Table 2. Characteristics of patients with cyclic neutropenia and Shwachman-Diamond syndrome

Subject	Age (y)	Gender	ANC ¹ /mm ³	AMC ² /mm ³	Platelets ³ × 10 ³ /mm ³	HCT ⁴ %	Elastase mutations		
							Exon/intron	Nucleotide ⁵	Effect on protein ⁶
Cyclic neutropenia (sporadic cases)									
1	23	M	246	928	330	41	Intron 4	G16073A	(ivs4 + 1sd) delV161-F170
2	26	M	122	740	255	35	Intron 4	G16073A	(ivs4 + 1sd) delV161-F170
3	4	F	178	816	416	33	Exon 4	C15862T	P110L
4	10	F	109	53	421	34	Intron 4	G16073A	(ivs4 + 1sd) del V161-F170
Mean	16		164	634	356	36			
SE	6		36	228	46	2			
Shwachman-Diamond syndrome									
1	4	M	201	206	191	22	No mutation		
2	8	F	324	215	120	36	No mutation		
3	4	F	452	339	299	32	No mutation		
Mean	5		326	253	203	30			
SE	2		89	53	64	5			

¹ANC indicates absolute neutrophil count. Measurement is the median of baseline counts.

²AMC indicates absolute monocyte count. Measurement is the median of baseline counts.

³Measurement is the median of baseline counts.

⁴Measurement is the median of baseline counts.

⁵Position of nucleotides for subjects 1-4 (mutations in intron 3-exon 5) corresponds to GenBank AC010648.

⁶ns indicates insertion; del, deletion; ivs, intervening sequence; sa, splice acceptor; sd, splice donor; fs, frame shift. Numbering is relative to the intron (negative)/exon (positive) boundary.

Amino acid numbering begins from the first amino acid after the presignal peptide cleavage.

and 12), a mother and a son (patient 9), and a mother (patient 10) with 2 affected sons with different fathers, suggesting autosomal dominant inheritance. The identical mutation has been found in the affected parent and child (or children) for all 5 of these families. Hematologic comparisons of the relatively large group of patients with mutations (22 patients) with the smaller group without mutations (3 patients) showed that the neutrophil counts were somewhat lower and the monocyte counts higher in patients with the mutant neutrophil *ELA2* gene, but the differences were not statistically significant. Seven of these mutations were predicted to alter RNA splicing or transcript structure. RT-PCR analysis using cells from the 5 available marrow samples demonstrated the predicted effect in each of these individuals (Figure 2).

The diversity in the mutations in congenital neutropenia was substantially greater than in patients with cyclic neutropenia. The mutations in the 4 sporadic cases of cyclic neutropenia shown in Table 2 and the 13 families with autosomal dominant cyclic neutropenia were predominantly in intron 4, creating splice donor mutations, or base substitutions near the junction of exon 4 and exon 5.⁸ One of the patients with congenital neutropenia (patient 22) with a mutation in intron 4 was at one time thought to have cyclic neutropenia based on a period of regularly recurring symptoms. The other child with a similar mutation (patient 21) was diagnosed in the first year of life as having congenital neutropenia without a long series of counts and then started on treatment. Based on examination of the tertiary structure of neutrophil elastase, the mutations in cyclic neutropenia appeared to cluster around the active site of the enzyme, whereas the mutations in congenital neutropenia were predominantly on




Figure 2. RT-PCR analysis of mutations affecting splicing and transcript structure. Each aberrant splicing product appearing on the agarose gel was isolated and sequenced to confirm the interpretation shown in the schematic. The genomic DNA mutations are depicted in green, the resulting cDNA aberration in red. Because no bone marrow was available from patients with the IVS4 + 3SD and IVS4-40SD mutations, the result shown is the predicted result. Note that patient 11 has a 5T insertion and patient 12 a 24-bp deletion, neither of which would be expected to alter splicing. Nevertheless, the 5T insertion produces at least 2 transcripts, one containing the 5T insertion and another unanticipatedly forcing utilization of the 2nd cryptic upstream splice donor site. For patient 12, whereas only 2 transcripts were identified (the normal and one containing the 24-bp deletion) following subcloning and sequencing, uncharacterized higher molecular weight products that presumably represent misprocessed primary transcripts are apparent.




Figure 3. Mutations in severe congenital neutropenia. Tertiary distribution of the severe congenital neutropenia (SCN) mutations (yellow) are compared to cyclic neutropenia/cyclic hematopoiesis (CH) mutations (red). Catalytic serine residue 173 is indicated in green near the active site pocket. The 2 figures are rotated 180° with respect to each other. The image was prepared from x-ray crystallographic coordinates taken from the Molecular Modeling DataBase (<http://www.ncbi.nlm.nih.gov/Structure/MMDB/mmdb.html>).

the molecule's opposite face (Figure 3), suggesting a correlation between the genotype and the phenotype.

With the diversity of mutations in congenital neutropenia, there was no clear correlation of the sites of the mutations and the patient's blood neutrophil counts or clinical courses. Patients 2, 5, and 20 from the group with mutations (3 of 21, or 14%) have developed acute myeloid leukemia (AML), a recognized complication in about 10% of patients with congenital neutropenia.¹¹ The neutropenic father of another patient (patient 12) has myelodysplasia. One of the 4 patients (25%) without a mutation (patient 24) has developed AML.

Schematic representation of neutrophil elastase structure with the positions of missense and deletion mutations is shown in Figure 4. Preliminary structural analysis suggests that all of the substitutions led to conformational changes. Substitution of glycine 185 with positively charged arginine in the immediate proximity to the active site, the C42S missense mutation, and the deletion of 8 amino acid fragments (V145-152) all probably alter biologic function. The 5 truncation and frame shift mutations in patients 15 through 19 remove the C-terminal portion of the molecule probably resulting in destabilization of the protein structure near the active site.




Figure 4. Ribbon diagram of neutrophil elastase with schematic representation of beta strands in complex with a peptide methoxysuccinyl-Ala-Ala-Pro-Ala chloromethyl ketone inhibitor. Purple balls and chain fragment represent missense and deletion mutations. Red balls represent positions of truncation mutations in congenital neutropenia (A) and cyclic neutropenia (B). See text for explanations of effects of mutations noted. Drawing by E. Adman, University of Washington, using MOLSCRIPT (P. Kraulis. Molscript: a program to produce both detailed and schematic plots of protein structure. J Appl Crystallogr. 1991;24:946-950) and Raster3D (Merritt EA, Murphy MEP. Raster3D Version 2.0 a program for photorealistic molecular graphics. Acta Crystallogr. 1994;D50:869-873).

None of the patients with Shwachman-Diamond syndrome had mutations. Additionally, only one coding sequence change in the gene for neutrophil elastase was observed in 230 control chromosomes from normal individuals, and this change is presumed to represent a polymorphism, because of its appearance also in a family with cyclic neutropenia in which a mutation found in other pedigrees segregates with disease.

Discussion

This report describes the occurrence of mutations of the gene encoding neutrophil elastase in 22 patients with severe congenital neutropenia and extends our previous observation of mutations of this gene in cyclic neutropenia.⁸ Previous research has suggested that the pathophysiology of congenital neutropenia may relate to mutations of the granulocyte colony-stimulating factor (G-CSF) receptor, based on finding the mutation before any evidence suggests the patient has myelodysplasia or evolving AML.¹² However, in almost all patients, G-CSF receptor mutations have been reported as acquired abnormalities detected in the process of evolution to AML.¹³ Current prevalence data suggest that a minority of patients manifest this mutation,^{14,15} and it now seems much more likely that mutations of the gene for neutrophil elastase lead to compromised myeloid differentiation and create the risk for development of AML. The familial cases reported here and the finding that heterozygous mutations are so consistently found in affected individuals suggest that both cyclic and most cases of congenital neutropenia have an autosomal dominant inheritance or are the result of a new dominant-acting germline mutation. The results also suggest that these are closely related disorders with overlapping molecular and clinical phenotypes. Visually and mathematically discernable oscillations in neutrophil counts are at times features of cases called “congenital neutropenia.”¹⁶ Similarly, affected family members with autosomal dominant cyclic neutropenia may be neutropenic without showing oscillations of their neutrophil counts.¹⁷ Oscillations in both of these disorders are usually accentuated by treatment with G-CSF.^{18,19}

The findings reported here suggest a primary role for mutations of neutrophil elastase in causing most, but not all, cases of severe congenital neutropenia. This protease is normally synthesized and packaged in promyelocytes at an early stage in neutrophil development.²⁰ Neutrophil elastase has many recognized and possible substrates, including coagulation proteins, growth factors, and intracellular signaling molecules.²¹ It is normally synthesized in the developing neutrophil as a proenzyme but stored in the primary granules in its active form, ready with full enzymatic activity when released from the granules, normally at sites of inflammation.^{22,23} The pathogenic role of mutant elastase in causing neutropenia may be directly linked to the poor survival characteristics of early

myeloid precursor cells in congenital and cyclic neutropenia.^{24,25} Accelerated apoptosis of promyelocytes and their progeny in vivo may explain the classic marrow finding of “promyelocytic arrest” in these conditions, but the specific protein-protein interactions causing these cellular abnormalities and causes for congenital neutropenia in patients without elastase mutations are yet to be discovered. The structural analysis presented here suggests that improper folding and destabilization of neutrophil elastase may be the critical effects of these mutations.

Oscillations in the hematopoietic system and the phenomenon of cyclic neutropenia have attracted the attention of clinicians and mathematicians for many years.²⁶ Although numerous mechanisms have been proposed, the data in this report fit best with the hypothesis that oscillations of peripheral neutrophil counts will occur when there is reduced survival of early hematopoietic precursor cells and an intact feedback control system governing blood cell levels.²⁷ This model assumes that neutrophil production is normally efficient, as indicated in careful quantitative studies.²⁸ When precursor cell survival is poor, that is, the apoptotic rate is high, production of cells is very inefficient, and the output of cells is low. This state matches the high rate of apoptosis observed in severe congenital neutropenia and in patients with Shwachman-Diamond syndrome.²⁹ Treatment with G-CSF can improve but does not completely reverse this defect in cell survival, probably through its antiapoptotic effect on myeloid cells.^{24,25} In cyclic neutropenia, the defect in cell survival is less severe, presumably because the mutant elastase less severely shortens precursor survival. In some individuals identified through family studies, either the cell survival may be better or the strength of the feedback loop weaker, resulting in no or substantially blunted oscillations. Because neither heterozygous nor homozygous neutrophil elastase knockout mice are neutropenic,³⁰ it is quite likely the mutations in congenital and cyclic neutropenia lead to a gain of function or aberrant function of the enzyme.

Congenital and cyclic neutropenia are rare disorders, but the mechanisms governing the regulation and deployment of neutrophils are of broad importance. Treatment with G-CSF has greatly reduced the problems of recurrent and severe infections for patients with severe chronic neutropenia³¹; better understanding of the genetic and molecular mechanisms of these disorders should lead to even better therapies.

Acknowledgments

We are grateful for the participation of the many physicians worldwide who contribute data to the Severe Chronic Neutropenia International Registry. We appreciate the assistance of Tammy Cottle and staff at the Severe Chronic Neutropenia International Registry, Carol Fier at Amgen, Inc, and Elin Rodger for her technical assistance.

References

- Leale M. Recurrent fungulosis in an infant showing an unusual blood picture. *JAMA*. 1910; 54:1844-1855.
- Rieman H, deBerardinis C. Periodic (cyclic) neutropenia, an entity. A collection of sixteen cases. *Blood*. 1949;4:1109-1116.
- Morley A, Carew J, Baikie A. Familial cyclic neutropenia. *Br J Haematol*. 1967;13:719-738.
- Dale D, Hammond W. Cyclic neutropenia: a clinical review. *Blood Rev*. 1988;2:178-185.
- Kostmann R. Infantile genetic agranulocytosis. *Acta Paediatr*. 1956;45(suppl 105):1-78.
- Welte K, Boxer L. Severe chronic neutropenia: pathophysiology and therapy. *Semin Hematol*. 1997;34:267-278.
- Briars C, Parry H, Ansari B. Dominantly inherited severe congenital neutropenia. *J Infect*. 1996;33: 123-126.
- Horwitz M, Benson K, Person R, Aprikyan A, Dale D. Mutations in *ELA2*, encoding neutrophil elastase, define a 21-day biological clock in cyclic haematopoiesis. *Nat Genet*. 1999;23:433-436.
- Jones TA, Zou JY, Cowan SW, Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. *Acta Crystallogr*. 1991;A47:110-119.
- Bernstein FC, Koetzal TF, Williams GJB, et al. The Protein Databank: a computer-based archival file for macromolecular structures. *J Mol Biol*. 1977;112:535-542.
- Freedman M. Safety of long-term administration of granulocyte-colony stimulating factor for severe chronic neutropenia. *Curr Opin Hematol*. 1997;4:217-224.
- Dong F, Brynes RK, Tidow N, Welte K, Lowenberg B, Touw IP. Mutations in the gene for the

- granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. *N Engl J Med.* 1995;333:487-493.
13. Tidow N, Pilz C, Teichmann B, et al. Clinical relevance of point mutations in the cytoplasmic domain of the granulocyte colony-stimulating factor receptor gene in patients with severe congenital neutropenia. *Blood.* 1997;89:2369-2375.
 14. Tidow N, Pilz C, Kasper B, Welte K. Frequency of point mutations in the gene for the G-CSF receptor in patients with chronic neutropenia undergoing G-CSF therapy. *Stem Cells.* 1997;15:113-119.
 15. Germeshausen M, Tidow N, Pilz C, Tschan C, Zeidler C, Welte K. G-CSF receptor mutations in patients with severe congenital neutropenia: frequency and implications in leukemic development. *Blood.* 1999;94:45a.
 16. Haurie C, Dale DC, Mackey MC. Occurrence of periodic oscillations in the differential blood counts of congenital, idiopathic and cyclic neutropenic patients before and during treatment with G-CSF. *Exp Hematol.* 1999;27:401-409.
 17. Palmer SE, Stephens K, Dale DC. Genetics, phenotype, and natural history of autosomal dominant cyclic hematopoiesis. *Am J Med Gen.* 1996;66:413-422.
 18. Bonilla MA, Gillio AP, Ruggeiro M, et al. Effects of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis. *N Engl J Med.* 1989;320:1574-1580.
 19. Hammond WP, Price TH, Souza LM, Dale DC. Treatment of cyclic neutropenia with granulocyte colony stimulating factor. *N Engl J Med.* 1989;320:1306-1311.
 20. Berliner N. Molecular biology of neutrophil differentiation. *Curr Opin Hematol.* 1998;5:49-53.
 21. Bieth J. Leukocyte elastase. In: Barret A, Rawlings N, Woessner J, eds. *Handbook of Proteolytic Enzymes.* San Diego: Academic Press; 1998: 54-60.
 22. Gullberg U, Andersson E, Garwicz D, Lindmark A, Olsson I. Biosynthesis, processing and sorting of neutrophil proteins: insight into neutrophil granule development. *Eur J Haematol.* 1997;58:137-153.
 23. Borregaard N, Cowland JB. Granules of the human neutrophilic polymorphonuclear leukocyte. *Blood.* 1997;89:3503-3521.
 24. Aprikyan AG, Liles WC, Rodger E, Dale DC. Cyclic neutropenia: proliferative and survival characteristics of bone marrow hematopoietic cells. *Blood.* 1998;92:699a.
 25. Aprikyan AG, Liles WC, Person RE, Rodger E, Dale DC. Accelerated apoptosis of bone marrow progenitor cells in severe congenital neutropenia. *Blood.* 1998;94:482a.
 26. Mackey MC. Unified hypothesis for the origin of aplastic anemia and periodic haematopoiesis. *Blood.* 1978;51:941-956.
 27. Haurie C, Dale DC, Mackey MC. Cyclical neutropenia and other periodic hematological disorders: a review of mechanisms and mathematical models. *Blood.* 1998;92:2629-2640.
 28. Dancy JT, Deubelbeiss KA, Harker LA, Finch CA. Neutrophil kinetics in man. *J Clin Invest.* 1976;58:705-715.
 29. Dror Y, Freedman M. Shwachman-Diamond syndrome: an inherited preleukemic bone marrow failure disorder with aberrant hematopoietic progenitors and faulty marrow microenvironment. *Blood.* 1999;94:3048-3054.
 30. Belaouaj A, McCarthy R, Baumann M, et al. Mice lacking neutrophil elastase reveal impaired host defense against gram negative bacterial sepsis. *Nat Med.* 1998;4:615-618.
 31. Dale DC, Bonilla MA, Davis MW, et al. A randomized controlled phase III trial of recombinant human G-CSF for treatment of severe chronic neutropenia. *Blood.* 1993;181:2496-2502.